Probi to launch Probi Digestis® in Brazil

Probi has signed a distribution agreement with Laboratório Daudt, the oldest
Brazilian pharmaceutical company with market presence since 130 years. Following
registration, Lab. Daudt plans to launch Probi Digestis® during 2015.

Probi AB and Lab. Daudt have agreed to launch the Swedish market leading
probiotic supplement – Probi Mage® – on the Brazilian market.

“Key to success in such a large market is distribution into the most important
of the 65 000 pharmacies, along with professional contacts with the
gastroenterology specialists. Lab. Daudt have these networks, and this is why
Probi is very pleased to sign with Daudt”, says Peter Nählstedt, CEO of Probi.

Brazil has a growing probiotic market larger than USD 60 million, 3 times the
size of the Swedish market, according to Euromonitor with several new players
succesfully launching new probiotic products why Brazil represents a key
opportunity in the years to come.

“IBS – Irritable Bowel Syndrome - has a prevalence in Brazil of more than 10
percent of the population and is consequently a very interesting category to
us,” says Gustavo Daudt, Vice President and 5thgeneration in Lab. Daudt. “We are
committed to gain market share in the years to come. Probi Digestis®has a large
number of positive clinical studies within gut health; among these, reduction or
elimination of symptoms associated with Irritable Bowel Syndrome.”

Probi Digestis® is based on Lactobacillus plantarum 299v (DSM 9843), targeting
bloating, gas formation and pain, all common symptoms that are sometimes mild or
temporary but often more severe and causing a low quality of life for people
suffering from such symptoms.

“Probi Digestis® will be launched under a specific IBS brand complementing Lab.
Daudt’s presence in the category,” Gustavo Daudt continues, adding: “We are
pleased to enter into a cooperation with Probi of Sweden, one of the leading
probiotic science companies in the industry.”

The information is such that Probi AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.

FOR FURTHER INFORMATION, CONTACT:
Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23 or mobile +46 723 86 99 83, e
-mail: peter.nahlstedt@probi.se
Niklas Bjärum, VP Marketing & Sales, Probi, tel +46 46 286 89 67 or mobile
+46 705 38 88 64, e-mail: niklas.bjarum@probi.se

ABOUT PROBI
Probi AB is a Swedish publicly traded biotechnology company that develops
effective and well-documented probiotics. Through its research, Probi has
created a strong product portfolio in the gastrointestinal health and immune
system areas. The products are available to consumers in more than 30 countries
worldwide. The customers are leading food, health-product and pharmaceutical
companies in the Functional Food and Consumer Healthcare segments. Probi had
sales of MSEK 102 in 2013. The Probi share is listed on NASDAQ OMX Stockholm,
Small-cap. Probi has approximately 4,000 shareholders. Read more on
www.probi.se.

ABOUT LABORATÓRIO DAUDT
Laboratório Daudt is a pharmaceutical manufacturer present in Brazil since 1882
with more than 300 employees and production capacity of over 40 million units
per year.  Daudt develops and markets branded pharmaceutical products, OTCs as
well as RX drugs. Visiting physicians all over the country, the company covers
many specialties including Gastroenterology, Orthopedics,  Gynaecologists,
Pediatricians, Surgeons, among others. Beside medicine, Daudt commercializes
cosmetics, medical devices and food suplements, for the health and well being of
patients. Read more on http://www.labdaudt.com.br/en/